{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:58:38Z","timestamp":1784743118968,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.07.040","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:59:52Z","timestamp":1695225592000},"page":"6762-6773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses"],"prefix":"10.1016","volume":"41","author":[{"given":"Bethanie","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gale","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2023.07.040_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0010","article-title":"Safety and efficacy of NVX-COV2373 Covid-19 vaccine","volume":"17","author":"Heath","year":"2021","journal-title":"NEJM"},{"issue":"24","key":"10.1016\/j.vaccine.2023.07.040_b0015","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"NEJM"},{"issue":"11","key":"10.1016\/j.vaccine.2023.07.040_b0020","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S1473-3099(22)00420-0","article-title":"Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Mallory","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.040_b0025","unstructured":"EMA. Summary of Product Characteristics (SmPC) Nuvaxovid. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nuvaxovid-epar-product-information_en.pdf. [Accessed 28 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0030","unstructured":"FDA. U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Novavax COVID-19 Vaccine, Adjuvanted, for active immunization to prevent COVID-19 in individuals 12 years of age; 2023. [Online]. Available: https:\/\/www.fda.gov\/media\/159897\/download."},{"key":"10.1016\/j.vaccine.2023.07.040_b0035","unstructured":"Fong Y, et al. Immune correlates analysis of the prevent-19 COVID-19 vaccine efficacy clinical trial, medRxiv 2022. [Online]. Available: 10.1101\/2022.06.22.22276362. [Accessed 28 September 2022]."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2023.07.040_b0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2023.07.040_b0045","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1016\/j.vaccine.2020.06.044","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines","volume":"38","author":"Kochhar","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.040_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.040_b0055","unstructured":"WHO. Weekly Epidemiological Record No. 28. Online Print 2019; 94: 310\u2013312."},{"key":"10.1016\/j.vaccine.2023.07.040_b0060","unstructured":"WHO. Weekly Epidemiological Record. No. 4. Online Print 2020; 95: 29\u201330."},{"key":"10.1016\/j.vaccine.2023.07.040_b0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(21)00192-4","article-title":"Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 Randomised Controlled Trial","volume":"22","author":"Shinde","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.040_b0070","article-title":"Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults","volume":"14","author":"Fries","year":"2017","journal-title":"Immun Ageing"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.040_b0075","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2023.07.040_b0080","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.040_b0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.07.040_b0090","unstructured":"Stertman L, et al. The Matrix-M\u2122 adjuvant: A critical component of vaccines for the 21stcentury. Hum Vaccin Immunother 2023."},{"key":"10.1016\/j.vaccine.2023.07.040_b0095","first-page":"1222","article-title":"Novavax NVX\u2013COV2373 triggers neutralization of Omicron","volume":"13","author":"Bhiman","year":"2023","journal-title":"Nat Sci Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.040_b0100","doi-asserted-by":"crossref","first-page":"e239135","DOI":"10.1001\/jamanetworkopen.2023.9135","article-title":"Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a Randomized Clinical Trial","volume":"6","author":"\u00c1\u00f1ez","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-cov2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2023.07.040_b0110","doi-asserted-by":"crossref","unstructured":"Smith K, et al. Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials. MedRxIV 2023.","DOI":"10.1101\/2023.02.24.23285601"},{"key":"10.1016\/j.vaccine.2023.07.040_b0115","unstructured":"EMA. Risk Management Plan (RMP) Nuvaxovid [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/nuvaxovid-epar-risk-management-plan_en.pdf. [Accessed 28 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ebiom.2021.103699","article-title":"Current and future nanoparticle vaccines for COVID-19","volume":"74","author":"Vu","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.07.040_b0125","unstructured":"CDC. Symptoms of COVID-19. 11 August 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html. [Accessed 28 September 2022]."},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/tomography8020084","article-title":"Systematic emergencies in COVID-19 patient: a pictoral review","volume":"8","author":"Albanesi","year":"2022","journal-title":"Tomography"},{"key":"10.1016\/j.vaccine.2023.07.040_b0135","unstructured":"CDC. People with Certain Medical Conditions. 2 September 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html. [Accessed 28 September 2022]."},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.040_b0140","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1002\/jmv.26951","article-title":"The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis","volume":"93","author":"Zhao","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.07.040_b0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in US children and adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.vaccine.2023.07.040_b0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15585\/mmwr.mm7023e1","article-title":"COVID-NET surveillance team. Hospitalization of adolescents aged 12\u201317 years with laboratory-confirmed COVID-19\u2014COVID-NET, 14 states, March 1, 2020\u2013April 24, 2021","volume":"70","author":"Havers","year":"2021","journal-title":"MMWR Morb Moral Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajog.2021.08.054","article-title":"An update on COVID-19 and pregnancy","volume":"226","author":"Jamieson","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.07.040_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-09826-8","article-title":"COVID-19 mortality risk for older men and women","author":"Yanez","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.07.040_b0165","unstructured":"CDC. COVID-19 after vaccination: possible breakthrough infection, 23 June 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html. [Accessed 22 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0170","doi-asserted-by":"crossref","unstructured":"Alcendor DJ, et al. Breakthrough COVID-19 infections in the US: Implications for prolonging the pandemic. Vaccines 2022; 10(755).","DOI":"10.3390\/vaccines10050755"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2023.07.040_b0180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ijid.2021.01.069","article-title":"The incubation period of COVID-19: A meta-analysis","volume":"104","author":"Elias","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.040_b0185","unstructured":"WHO. Coronavirus disease (COVID-19), 13 May 2021. [Online]. Available: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/question-and-answers-hub\/q-a-detail\/coronavirus-disease-covid-19. [Accessed 22 September 2022]."},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.040_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac052","article-title":"Shorter serial intervals and incubation periods in SARS-CoV-2 variants than the SARS-CoV-2 ancestral strain","volume":"29","author":"Du","year":"2022","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.07.040_b0195","unstructured":"CDC. Science Brief:SARS-CoV-2 Transmission, 7 May 2021. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/sars-cov-2-transmission.html. [Accessed 28 September 2022]."},{"issue":"34","key":"10.1016\/j.vaccine.2023.07.040_b0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2023.07.040_b0205","unstructured":"CDC. Variants of the Virus, 11 August 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fomicron-variant.html#print. [Accessed 28 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0210","unstructured":"CDC. Ending isolation and precautions for people with COVID-19: Interim Guidance, 31 August 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/duration-isolation.html#:\u223c:text=Infectiousness%20peaks%20around%20one%20day,8%20days%20after%20symptom%20onset. [Accessed 28 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0215","unstructured":"CDC. COVID-19 science update asymptomatic transmission, 12 June 2022. [Online]. Available: https:\/\/www.cdc.gov\/library\/covid19\/061220_covidupdate.html. [Accessed 28 September 2022]."},{"issue":"11","key":"10.1016\/j.vaccine.2023.07.040_b0220","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3390\/v13112133","article-title":"Dynamics of viral shedding and symptoms in patients with asymptomatic or mild COVID-19","volume":"13","author":"Bae","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.040_b0225","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1093\/cid\/ciab100","article-title":"Acute respiratory syndrome coronoavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.040_b0230","article-title":"Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear","volume":"375","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2023.07.040_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239800","article-title":"Global convergence of COVID-19 basic reproduction number and estimation from early dynamics","volume":"15","author":"Katul","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.040_b0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3961\/jpmph.20.076","article-title":"Estimate of the basic reproduction number for COVID-19: a systematic review and meta-analysis","volume":"53","author":"Alimohamadi","year":"2020","journal-title":"J Prev Med Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.040_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248731","article-title":"Estimating the basic reproduction number for COVID-19 in Western Europe","volume":"16","author":"Locatelli","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.040_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264455","article-title":"The basic reproduction number of COVID-19 across Africa","volume":"17","author":"Iyaniwura","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.07.040_b0255","unstructured":"Johns Hopkins University, \u201cCoronavirus Resource Center,\u201d [Online]. Available: https:\/\/coronavirus.jhu.edu\/. [Accessed 20 May 2022]."},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.040_b0260","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10654-020-00698-1","article-title":"Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications","volume":"35","author":"Levin","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.07.040_b0265","unstructured":"CCDC. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) \u2014 China, 2020. CCDCWeekly, 2020."},{"key":"10.1016\/j.vaccine.2023.07.040_b0270","unstructured":"CDC. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group, 25 April 2023. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-age.html#print. [Accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0275","unstructured":"CDC. Risk for COVID-19 Infection, Hospitalization, and Death by Race\/Ethnicity, 8 November 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-race-ethnicity.html#print. [Accessed 8 November 2022]."},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.040_b0280","doi-asserted-by":"crossref","first-page":"e2036462","DOI":"10.1001\/jamanetworkopen.2020.36462","article-title":"Association of social and demographic factors with COVID-19 incidence and death rates in the US","volume":"4","author":"Karmakar","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.07.040_b0285","unstructured":"CDC. Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity, 29 October 2021. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/vaccine-induced-immunity.html. [Accessed 28 September 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0290","doi-asserted-by":"crossref","unstructured":"Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 2020.","DOI":"10.20944\/preprints202004.0377.v1"},{"key":"10.1016\/j.vaccine.2023.07.040_b0295","doi-asserted-by":"crossref","unstructured":"Karbiener M, et al. Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. Vaccines 2022; 7(22).","DOI":"10.1038\/s41541-022-00455-3"},{"key":"10.1016\/j.vaccine.2023.07.040_b0300","unstructured":"CDC. Reinfection, 19 October 2022. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/clinical-considerations-reinfection.html#print. [Accessed 30 March 2023]."},{"issue":"10318","key":"10.1016\/j.vaccine.2023.07.040_b0305","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.040_b0310","doi-asserted-by":"crossref","unstructured":"Khavinson V, et al. Homology between SARS-CoV-2 and human proteins, 2021. [Online]. Available: 10.1038\/s41598-021-96233-7.","DOI":"10.1038\/s41598-021-96233-7"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.040_b0315","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/vaccines9030222","article-title":"Natural and synthetic saponins as vaccine adjuvants","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines"},{"issue":"6520","key":"10.1016\/j.vaccine.2023.07.040_b0320","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.abe1502","article-title":"Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate","volume":"370","author":"Bangaru","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.07.040_b0325","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.biopha.2018.06.026","article-title":"Efficacy and safety of immunological adjuvants. Where is the cut-off?","volume":"105","author":"Batista-Duharte","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"22","key":"10.1016\/j.vaccine.2023.07.040_b0330","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Brighton Collaboration Vaccine-associated Enhanced Disease Working Group. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2023.07.040_b0335","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.040_b0340","unstructured":"Australian Govt. Dept. of Health and Aged Care, Nuvaxovid (Novavax), 2022. [Online]. Available: https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/approved-vaccines\/novavax#rare-side-effects. [Accessed 8 November 2022]."},{"key":"10.1016\/j.vaccine.2023.07.040_b0345","doi-asserted-by":"crossref","first-page":"988","DOI":"10.15585\/mmwr.mm7131a2","article-title":"Interim recommendation of the advisory committee on immunization practices for use of the Novavax COVID-19 vaccine in persons aged \u226518 years \u2014 United States, July 2022","volume":"71","author":"Twentyman","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300871X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300871X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:56Z","timestamp":1759404716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300871X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":69,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X2300871X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}